top of page
All posts
Alzheimer's
ANVISA
Author: Allan Matsui
Author: Jairo Utimi
Author: Claudia Cilento
Author: Nilva Bortoleto
BPF
Cannabidiol
Cancer
Cannabis
Coronavirus
Covid-19
challenges
Epilepsy
pharmaceutical
IFA
pharmaceutical industry
Inovatie
medicines
opportunities
Parkinson
pharmaceuticals
pharmaceutical industry
Author: Camille Rodrigues da Silva
Incremental innovation
Investments
Marketing
News
Incremental innovation
Good Manufacturing Practices
Search
What is important about the new regulatory framework for good manufacturing practices?
Feb 9, 2021
Cannabis for therapeutic uses: is this a new market?
Feb 9, 2021
Outcome of the RDC 200 Review Working Group meeting - 02/05/20
Feb 9, 2021
Cannabis: the rules of the new regulation system.
Feb 9, 2021
Everything you need to know about the new rules for Drug Renewal.
Feb 9, 2021
Clinical studies for health devices: 5 value tips
Feb 9, 2021
Demystifying INMETRO and ANATEL certification for health products
Feb 9, 2021
API: Why control it?
Feb 9, 2021
CTD - Why?
Feb 9, 2021
Which points generate the most rejections and demands in innovative drug processes?
Feb 9, 2021
DDCM: what are the points that generate the most demands at ANVISA (Part 2)?
Feb 9, 2021
DDCM- What are the most demanding requirements by ANVISA?
Feb 9, 2021
Biosimilars - An investment with excellent long-term prospects
Feb 9, 2021
Biosimilars - Can Marketing activities make a Difference? 6 reflections on the theme
Feb 9, 2021
Practical aspects of biosimilar registration
Feb 9, 2021
Comparability of biosimilars: unraveling this enigma
Feb 9, 2021
The biotechnological challenge of the national pharmaceutical industry has already begun
Feb 9, 2021
ANVISA’S new era: is the regulatory sector prepared for this?
Feb 9, 2021
New Efficacy and Safety Analysis Roadmap for Synthetic Drug Registration
Feb 9, 2021
Clinical Research in Brazil: there is still a lot of room to grow
Feb 9, 2021
1
2
3
4
5
E-BOOKS
CONTEÚDOS EXCLUSIVOS PARA AUXILIAR EM
SEU TRABALHO
Acesse
bottom of page
